Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1756-8722

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target ; volume:14 ; number:1 ; day:15 ; month:9 ; year:2021 ; pages:1-17 ; date:12.2021
Journal of hematology & oncology ; 14, Heft 1 (15.9.2021), 1-17, 12.2021

Creator: Qian, Wenjing
Zhao, Mingfang
Wang, Ruoyu
Li, Heming

Contributor: SpringerLink (Online service)

DOI: 10.1186/s13045-021-01161-8

URN: urn:nbn:de:101:1-2021112700342009123364

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:28 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Qian, Wenjing
Zhao, Mingfang
Wang, Ruoyu
Li, Heming
SpringerLink (Online service)

Other Objects (12)

Next generation of immune checkpoint inhibitors and beyond

Resistance to immune checkpoint inhibitors. Next steps and combinational approaches

Galectin-3: an immune checkpoint target for musculoskeletal tumor patients

GPCRs: emerging targets for novel T cell immune checkpoint therapy

Next generation of immune checkpoint therapy in cancer: new developments and challenges

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy

Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer

Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy

Neurosarcoidosis following Immune Checkpoint Inhibition

Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity

Next generation of immune checkpoint inhibitors and beyond

Resistance to immune checkpoint inhibitors. Next steps and combinational approaches

Galectin-3: an immune checkpoint target for musculoskeletal tumor patients

GPCRs: emerging targets for novel T cell immune checkpoint therapy

Next generation of immune checkpoint therapy in cancer: new developments and challenges

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy

Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer

Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy

Neurosarcoidosis following Immune Checkpoint Inhibition

Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity

Next generation of immune checkpoint inhibitors and beyond

Resistance to immune checkpoint inhibitors. Next steps and combinational approaches

Galectin-3: an immune checkpoint target for musculoskeletal tumor patients

GPCRs: emerging targets for novel T cell immune checkpoint therapy

Next generation of immune checkpoint therapy in cancer: new developments and challenges

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy

Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer

Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy

Neurosarcoidosis following Immune Checkpoint Inhibition

Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Next generation of immune checkpoint inhibitors and beyond

Resistance to immune checkpoint inhibitors. Next steps and combinational approaches

Galectin-3: an immune checkpoint target for musculoskeletal tumor patients

GPCRs: emerging targets for novel T cell immune checkpoint therapy

Next generation of immune checkpoint therapy in cancer: new developments and challenges

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy

Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer

Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy

Neurosarcoidosis following Immune Checkpoint Inhibition

Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity

Next generation of immune checkpoint inhibitors and beyond

Resistance to immune checkpoint inhibitors. Next steps and combinational approaches

Galectin-3: an immune checkpoint target for musculoskeletal tumor patients

GPCRs: emerging targets for novel T cell immune checkpoint therapy

Next generation of immune checkpoint therapy in cancer: new developments and challenges

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy

Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer

Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy

Neurosarcoidosis following Immune Checkpoint Inhibition

Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity

Next generation of immune checkpoint inhibitors and beyond

Resistance to immune checkpoint inhibitors. Next steps and combinational approaches

Galectin-3: an immune checkpoint target for musculoskeletal tumor patients

GPCRs: emerging targets for novel T cell immune checkpoint therapy

Next generation of immune checkpoint therapy in cancer: new developments and challenges

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy

Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer

Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy

Neurosarcoidosis following Immune Checkpoint Inhibition

Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity

Related objects

Reset password